$MNOV..MediciNova's MN-001 (tipelukast) NASH Abstract Selected for Late-Breaking Session at the 65th Annual AASLD Meeting in Boston
LA JOLLA, Calif., Oct. 6, 2014 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (Nasdaq:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number:4875), today announced that it has been invited to and will present data on MN-001 (tipelukast) during the late-breaking poster session at the 65th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), to be held November 7 – 11 in Boston.
In August 2014, MediciNova announced positive results from a mouse model that examined the potential clinical efficacy of MN-001 for the treatment of advanced NASH (nonalcoholic steatohepatitis with fibrosis). In this presentation, MediciNova will present detailed information about the effectiveness of MN-001 (tipelukast) in the NASH model.
Presentation details are as follows:
Presentation: "MN-001 (tipelukast), a novel, orally bioavailable drug, reduces fibrosis and inflammation and down-regulates TIMP-1, collagen Type 1 and LOXL2 mRNA overexpression in an advanced NASH (nonalcoholic steatohepatitis) model"
Session Date: Monday, November 10, 2014
Session: Late-Breaking Poster Session
Room: John B. Hynes Convention Center, Hall C
Sheff's Station...All Aboard...Sign Up Here!